We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Enhanced Immune System Activity Prevents Tumor Growth in Aged Mice

By LabMedica International staff writers
Posted on 23 Apr 2012
Results obtained from studies carried out on mice indicate that it may be possible to stimulate the immune system of elderly individuals so that they become able to respond to anticancer therapy in a manner similar to younger subjects.

Modulating the activity of T regulatory (Treg) cells, which are components of the immune system that suppress immune responses of other cells and act as an important “self-check” built into the immune system to prevent excessive reactions, has been shown to increase the success of chemotherapy in young subjects but not in their elderly counterparts.

To explain this finding, investigators at the University of Texas Health Science Center (San Antonio, USA) worked with selected young and aged mouse populations. More...
They confirmed that depletion of Tregs improved immune response in young animals without benefiting the elderly mice. However, results published in the April 15, 2012, issue of the journal Cancer Research, explained the reason for this.

Depletion of Treg activity in the elderly mice caused a massive increase in another type of immune suppressor cell: myeloid-derived suppressor cells (MDSCs). These cells, which do not proliferate in the young animals, maintained the relative inefficiency of the aged immune system. Treating the aged mice with both a drug to block Treg activity and a monoclonal antibody that caused MDSC depletion improved tumor-specific immunity and reduced melanoma tumor growth in the aged mice.

“We have shown that an aged immune system can combat cancer just as well as a young one if you remove the impediments to successful immunity, which are different that those in younger hosts,” said senior author Dr. Tyler Curiel, professor of medicine at the University of Texas Health Science Center. “We have shown that if you test all your immune therapy just in young mice and young people, you will never learn how it works in older patients — the ones most at risk for cancer. You might conclude that drugs do not work in aged hosts, when they do. But they have to be combined with some help.”

While this approach was successful for treating melanoma, a different monoclonal antibody was required for colon cancer.

“The details were different in colon cancer. The bad immune cells that increased in the aged mice and how they were knocked down by the drugs were different than in melanoma,” said Dr. Curiel. “But the result was the same — we identified a drug combination that was highly effective in the aged mice. It is a bit complicated, but it is possible to put into practice, and because these approaches could be so much more specific and so much better tolerated than conventional chemotherapy, it is well worth pursuing.”

Related Links:
University of Texas Health Science Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.